oprozomib + sorafenib

**Oprozomib + sorafenib is an investigational oral combination therapy for advanced hepatocellular carcinoma and other solid tumors, comprising two small molecules with distinct mechanisms.** Oprozomib is a next-generation oral proteasome inhibitor that induces cell cycle arrest and apoptosis by blocking proteasomal protein degradation, interfering with the unfolded protein response (UPR), and enhancing ER stress selectively in tumor cells. Sorafenib is an oral multikinase inhibitor that targets RAF, vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptor (PDGFR), suppressing tumor angiogenesis and proliferation. This combination has been investigated in phase 1/2 studies for synergistic anti-tumor efficacy, with clinical interest especially in hepatocellular carcinoma[4][5][6][7][8].

Brand names

Nexavar (for sorafenib; no marketed brand name for oprozomib as of 2025)

Other names

oprozomib + sorafenib